FGF23-regulated production of Fetuin-A (AHSG) in osteocytes

Mattinzoli, D., Rastaldi, M.P., Ikehata, M., Armelloni, S., Pignatari, C., Giardino, L.A., Li, M., Alfieri, C.M., Regalia, A., Riccardi, Daniela ORCID: https://orcid.org/0000-0002-7322-3163 and Messa, P. 2016. FGF23-regulated production of Fetuin-A (AHSG) in osteocytes. Bone 83 , pp. 35-47. 10.1016/j.bone.2015.10.008

Preview

PDF - Accepted Post-Print Version Download (2MB) | Preview

Abstract

Introduction: AHSG, a serum glycoprotein with recognized anti-calcification activity, has also been suggested to modulate both bone formation and resorption. Though the bulk of AHSG is mostly synthesized in the liver, it has been claimed that also bone cells might produce it. However, the extent of the bone AHSG production and the potential controlling factors remain to be definitively proven. A relevant number of studies support the notion that FGF23, a bone-derived hormone, not only regulates the most important mineral metabolism (MM) related factors (phosphate, parathyroid hormone, vitamin D, etc.), but might be also involved in cardiovascular (CV) outcome, both in chronic kidney disease (CKD) patients and in the general population. Furthermore, in addition to some direct autocrine and paracrine effects in bone, FGF23 has been suggested to interact with AHSG. In this study we investigated if AHSG is really produced by bone cells, and if its bone production is related and/or controlled by FGF23, using cultured bone cells, according to a new method recently published by our group. Results: Our data show that AHSG is consistently produced in osteocytes and to a far lesser extent in osteoblasts. Both FGF23 addition to the culture medium and its over-expression in osteocytes were associated with a consistent increase of both AHSG mRNA and protein, while FGF23 silencing was followed by opposite effects. Though most of these results were largely affected by the blockage of FGF23 receptors, the role of these receptors in the different experimental sets is still not completely clarified. In addition, we found that FGF23 and AHSG proteins co-localized both in cytoplasm and nucleus, which suggests a possible reciprocal interactivity. Conclusions: Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time that its production is modulated by FGF23. Since both proteins play important roles in the bone and cardiovascular pathology, these results add new pieces to the puzzling relationship between bone and vascular pathology, in particular in CKD patients, prompting future investigations in this field.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Additional Information:	PDF uploaded in accordance with publisher's policies at http://www.sherpa.ac.uk/romeo/issn/8756-3282/ (accessed 22.01.16).
Publisher:	Elsevier
ISSN:	8756-3282
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	13 October 2015
Last Modified:	07 Nov 2023 17:07
URI:	https://orca.cardiff.ac.uk/id/eprint/80160

Citation Data

Cited 22 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item